1. Belloni A, Morgan D, Paris V. Pharmaceutical expenditure and policies. Paris: Organisation for Economic Co-operation and Development; 2016 Apr.
http://www.oecd-ilibrary.org/content/workingpaper/5jm0q1f4cdq7-en
. Accessed 27 Jun 2018.
2. World Health Organization, Department of Essential Medicines and Health Products. WHO guideline on country pharmaceutical pricing policies. 2015.
http://apps.who.int/iris/bitstream/10665/153920/1/9789241549035_eng.pdf?ua=1
. Accessed 27 Jun 2018.
3. Pettigrew LM, Mathauer I. Voluntary health insurance expenditure in low- and middle-income countries: exploring trends during 1995–2012 and policy implications for progress towards universal health coverage. Int J Equity Health. 2016;15:67.
https://doi.org/10.1186/s12939-016-0353-5
.
4. Holtorf A-P, Brixner D, Bellows B, Keskinaslan A, Dye J, Oderda G. Current and future use of HEOR data in healthcare decision-Making in the United States and in emerging markets. Am Health Drug Benefits. 2012;5:428–38.
5. Hill S, Kieny MP. Towards access 2030. Lancet. 2017;389:341–3.